TP53 Mutations in Myeloid Neoplasms: From Clonal Hematopoiesis to Acute Leukemia

Log in for pricing

(No reviews yet) Write a Review
SKU:
321EEB24-016



Free for members and $29 for nonmembers


This interactive live webinar is part 16 of the Emerging and Evolving Biomarkers Series

Description:

This session will review the molecular pathogenesis of TP53 mutations in myeloid neoplasms, including the implications of the mutation in pre-malignant clonal myeloid proliferations, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).  The role of molecular testing and nuances in interpreting different types of TP53 mutations will be discussed.  The session will also review the implications of TP53 mutation on the classification,  prognosis, and prediction of treatment response of myeloid neoplasms, particularly MDS and AML.

Learning Objectives:
  • Associate the presence of TP53 mutation in hematopoietic cells with diverse disease phenotypes.
  • Classify the spectrum of TP53 mutations with respect to allele state, variant allele frequency, and mutation types.
  •  Apply the results of TP53 mutation testing to the classification and prognostic risk stratification of myeloid neoplasms, particularly myelodysplastic syndromes and acute myeloid leukemia.


Speaker:

Robert Hasserjian, MD
Massachusetts General Hospital




Moderator:
Rena Xian, MD
Johns Hopkins University



Duration: 1 Hour
Level of Instruction: Intermediate
Live webinar: June 20, 2024
Date Recorded: June 20, 2024


How to Register:
  1. Click the "Access Webinar Here!" Button
  2. Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account.
  3. Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.

Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to claim credit: December 31, 2026

Accreditation Statements
AMA PRA Category 1 Credit(s)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.

*NEW* Nonmembers may register for this webinar for $29
AMP Members may register for free